AT-406 (SM-406): Orally Bioavailable IAP Inhibitor for Cancer Research

Executive Summary: AT-406 (SM-406) is a small-molecule antagonist that inhibits multiple inhibitor of apoptosis proteins (IAPs), including XIAP, cIAP1, and cIAP2, with nanomolar affinity (AT-406 product page). It induces rapid cIAP1 degradation, activates caspase-dependent apoptotic pathways, and inhibits tumor growth in both in vitro and in vivo models (bioRxiv 2024). AT-406 shows oral bioavailability and tolerability in animal and human studies, with clinical doses up to 900 mg. It sensitizes ovarian cancer cells to carboplatin and prolongs survival in mouse xenograft models. AT-406 is a research tool for apoptosis modulation and drug development targeting IAP signaling (see advanced workflows).

Biological Rationale

Inhibitor of apoptosis proteins (IAPs) are a family of endogenous regulators that suppress apoptosis by binding and inhibiting caspases 3, 7, and 9 (bioRxiv 2024). Overexpression of IAPs, notably XIAP, cIAP1, and cIAP2, is documented in multiple cancer types and is associated with resistance to chemotherapy and poor prognosis. IAPs modulate not only apoptosis but also cell division, cycle progression, and signal transduction. Targeting IAPs is a validated approach to restore the apoptotic response in cancer cells. Small-molecule IAP antagonists can potentiate the effect of chemotherapeutic agents and overcome intrinsic or acquired resistance. The rational design of AT-406 (SM-406) leverages the structural homology of IAP BIR domains to achieve multi-targeted inhibition with high affinity.

Mechanism of Action of AT-406 (SM-406)

AT-406 (SM-406) is a monovalent, Smac-mimetic compound that binds to the baculoviral IAP repeat (BIR) domains of XIAP, cIAP1, and cIAP2. The compound exhibits Ki values of 66.4 nM for XIAP, 1.9 nM for cIAP1, and 5.1 nM for cIAP2, indicating high potency under standardized in vitro conditions (pH 7.4, 25°C) (A3019 product page). Upon binding, AT-406 displaces IAPs from caspases, restoring caspase-3, -7, and -9 activity and promoting apoptosis. The compound rapidly induces autoubiquitination and proteasome-mediated degradation of cIAP1, further amplifying apoptotic signaling. In cell-based assays, AT-406 triggers PARP cleavage and DNA fragmentation within 24 hours at concentrations of 0.1–3 μM. In the presence of chemotherapeutic agents such as carboplatin, AT-406 enhances apoptosis synergistically in resistant ovarian cancer cells. The molecular weight of AT-406 is 561.71 Da. It is soluble in DMSO and ethanol (≥27.65 mg/mL), but insoluble in water, supporting its suitability for organic solvent-based delivery systems.

Evidence & Benchmarks

• AT-406 inhibits XIAP, cIAP1, and cIAP2 with Ki values of 66.4 nM, 1.9 nM, and 5.1 nM, respectively, in biochemical binding assays (A3019 product page).
• In vitro, AT-406 induces apoptosis in human ovarian cancer cell lines with IC50 values of 0.05–0.5 μg/mL (24 h, RPMI-1640, 10% FBS, 37°C) (bioRxiv 2024).
• AT-406 sensitizes ovarian cancer cells to carboplatin, reducing the effective dose needed for apoptosis induction (CM-EGFP Probe 2024).
• In mouse xenograft models (NOD/SCID, 8-week-old, oral gavage), AT-406 significantly inhibits tumor progression and prolongs survival in ovarian and breast cancer models (dosing: 10–100 mg/kg daily) (bioRxiv 2024).
• Clinical studies report oral administration of AT-406 at doses up to 900 mg is well tolerated in patients with advanced solid tumors (A3019 product page).

For a more strategic perspective on integrating IAP inhibition into translational oncology, see this mechanistic review, which this article extends by providing updated quantitative preclinical and clinical benchmarks.

Applications, Limits & Misconceptions

AT-406 serves as a tool compound for dissecting apoptosis pathways, validating IAPs as therapeutic targets, and developing combination regimens in cancer models. It is used to:

• Evaluate caspase activation and apoptotic markers in cell-based assays (e.g., PARP cleavage, Annexin V staining).
• Sensitize tumor cells to chemotherapeutics in vitro and in vivo.
• Assess oral bioavailability and pharmacodynamics in preclinical species.
• Benchmark IAP inhibition as a strategy in translational oncology.

For workflows focused on apoptosis pathway activation and experimental troubleshooting, see this practical guide; this article provides more granular benchmarks and expands on clinical tolerability data.

Common Pitfalls or Misconceptions

• AT-406 is not effective in IAP-independent tumor cell lines: Tumors lacking functional expression of XIAP, cIAP1, or cIAP2 may not respond.
• It does not directly induce necrosis or autophagy: Apoptosis remains the primary death pathway triggered.
• Water-based delivery is not feasible: AT-406 is insoluble in water; DMSO or ethanol are required as solvents.
• Long-term storage in solution is discouraged: Stability is optimal as a solid at -20°C; solutions should be prepared fresh for short-term use.
• Not a substitute for immune checkpoint inhibitors: AT-406 targets apoptosis machinery, not immune checkpoints or T cell activation pathways.

Workflow Integration & Parameters

Typical in vitro experiments use AT-406 at 0.1–3 μM for 24 hours to assess apoptosis and caspase activation. For combination studies, carboplatin or other chemotherapeutics are added at sub-lethal doses to determine synergy. In vivo, dosing regimens range from 10–100 mg/kg orally, with tumor volume and survival as primary endpoints. All treatments should use vehicles compatible with AT-406 solubility, such as DMSO or ethanol-based formulations, and negative controls with vehicle only. Solutions should be prepared immediately before use (A3019 kit instructions). Storage at -20°C as a solid is recommended. For advanced strategies, researchers should consult this structural analysis, which this article clarifies by linking dosing parameters to molecular mechanism benchmarks.

Conclusion & Outlook

AT-406 (SM-406) is a validated, orally bioavailable IAP inhibitor for research in apoptosis modulation and cancer drug development. Its well-defined mechanism and robust preclinical data support its use for mechanistic studies and translational oncology workflows. Future directions include evaluating AT-406 in combination with immune-modulatory agents and expanding its utility in non-cancer models of apoptosis dysregulation. For more on IAP inhibition in tumor immunity, see this article, which this review updates by incorporating the latest clinical and preclinical findings.